Analysts Are Bullish on These Healthcare Stocks: SOPHiA GENETICS (SOPH), Verastem (VSTM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on SOPHiA GENETICS (SOPH – Research Report), Verastem (VSTM – Research Report) and Neurocrine (NBIX – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SOPHiA GENETICS (SOPH)
In a report released yesterday, William Bonello from Craig-Hallum maintained a Buy rating on SOPHiA GENETICS. The company’s shares closed last Monday at $5.15.
According to TipRanks.com, Bonello is a 5-star analyst with an average return of
Currently, the analyst consensus on SOPHiA GENETICS is a Strong Buy with an average price target of $7.00.
See today’s best-performing stocks on TipRanks >>
Verastem (VSTM)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Verastem on January 8 and set a price target of $15.00. The company’s shares closed last Monday at $7.11.
According to TipRanks.com, Timashev is a 5-star analyst with an average return of
Verastem has an analyst consensus of Strong Buy, with a price target consensus of $15.60, representing a 101.6% upside. In a report issued on December 30, Guggenheim also maintained a Buy rating on the stock with a $14.00 price target.
Neurocrine (NBIX)
In a report issued on January 8, Brian Abrahams from RBC Capital maintained a Buy rating on Neurocrine, with a price target of $180.00. The company’s shares closed last Monday at $132.66.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Currently, the analyst consensus on Neurocrine is a Strong Buy with an average price target of $179.84, a 33.0% upside from current levels. In a report issued on January 8, Truist Financial also maintained a Buy rating on the stock with a $169.00 price target.
